|
| |
TL VenturesWith over $1.4 billion under management, we have been actively engaged in the business of venture capital since 1988, investing in over 200 companies to date. Our network of approximately 50 active portfolio companies, investment resources, professional contacts and service providers makes us one of the most active firms in the market.
TL Ventures invests in companies led by outstanding management teams capable of building category-defining businesses in the software, information technology infrastructure and services, communications and biotechnology industries. Our team of investment professionals offers an extensive network of nationwide contacts and resources. We also assist early stage companies with business and product strategy, recruiting, technology partnerships, business and channel development and financing.
At TL Ventures, we are committed to working in partnership with our companies as they grow from concepts to successful organizations. The results achieved by our portfolio companies, showcases the success of our approach.
With hands-on experience in start-ups, engineering, operations, marketing and finance, our team of capable investment professionals is uniquely qualified to support you in the boardroom and day-to-day management. We understand entrepreneurs because many of our investment professionals have themselves started companies and subsequently taken them public or guided them through successful mergers or acquisitions.
| Contact Details: |
| 435 Devon Park Drive700 Building |
| Wayne |
| Pennsylvania |
| 19087-1990 |
| United States of America |
| Tel: | 610.971.1515 |
| Fax: | 610.975.9330 |
| Email: | info@tlventures.com |
| WWW: | www.tlventures.com/
|
|
Loading...
|
Press Releases on TL Ventures:
|
 |
| Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch |
16th October, 2009 |
Frost & Sullivan |
MOUNTAIN VIEW, Calif., Oct. 16 /PRNewswire/ -- Based on its annual assessment of companies making innovative contributions in healthcare, Frost & Sullivan recognizes Agile Therapeutics, Inc.
|
| Sopherion Therapeutics Secures $55 Million in Series C Funding |
19th February, 2009 |
Sopherion Therapeutics, LLC |
PRINCETON, N.J., Feb. 19 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, has announced a $55 million
|
| Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch |
3rd September, 2008 |
Agile Therapeutics, Inc. |
PRINCETON, N.J., Sept. 3 /PRNewswire/ -- Agile Therapeutics, Inc.,
announced today that it successfully completed two key clinical trials in the
development of the company's new, innovative
|
| Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million |
28th July, 2008 |
Celator Pharmaceuticals |
PRINCETON, N.J., July 28 /PRNewswire-FirstCall/ -- Celator
Pharmaceuticals, a privately held pharmaceutical company developing novel
products based on proven combinations of chemotherapeutic drugs
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 346 times since April 2007, the link to the organisation's website has been followed 83 times Recent Search Terms used to find this page: tl ventures | . Search for more companies in Wayne Search for more companies in Pennsylvania This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for TL Ventures |
